Drug Information

Drug General Information
Drug ID
D0BG3B
Former ID
DIB008930
Drug Name
VX-135
Indication HCV infection [ICD9: 070.4, 070.5, 070.70; ICD10:B17.1, B18.2] Phase 2 [524122]
Company
Vertex pharmaceuticals
Target and Pathway
Target(s) Hepatitis C virus NS5B polymerase Target Info Inhibitor [525394]
References
Ref 524122ClinicalTrials.gov (NCT01726946) A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C. U.S. National Institutes of Health.
Ref 525394All-oral HCV therapies near approval. Nat Rev Drug Discov. 2013 Jun;12(6):409-11. doi: 10.1038/nrd4036.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.